Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.

Abstract: The invention provides methods for the treatment of coronary heart disease, peripheral vascular disease, stroke, and ischemia featuring agents that interfere with the expression or activity of Cthrc1. The invention also provides the use of Cthrc1 peptide as a therapeutic agent for the treatment of acute or chronic cardiac deficiencies. The invention further provides detection and monitoring of Cthrc1 peptide in blood or serum to assess or monitor cardiac function.

Abstract: The present disclosure relates to a method of treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a peptide of the type TLQP-21 to the receptor qC1qR. The disclosure also relates to and methods of screening for said inhibitors.

Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.

Abstract: The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.

Abstract: This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.

Abstract: Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNF?) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNF? and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.

Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.

Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.

Abstract: The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.

Abstract: Disclosed herein are methods and compositions related to single chain antibody fragments which specifically bind sialyl-Tn epitope of tumor-associated glycoprotein 72 (TAG-72).

Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

Abstract: The present disclosure relates to anti-IgE antibodies that bind to novel antigenic epitopes of the CsmX domain, e.g., SVPHPRCHCGAGRA (SEQ ID NO: 4) and the uses thereof in treating IgE-mediated diseases.

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.

Abstract: Provided is a bioprocessing device including a hybrid of (1) a protein having a redox potential; and (b) a single strand DNA (ssDNA) conjugated to the protein. The bioprocessing device of the present invention has a function of information reinforcement, information regulation, or information amplification. This bioprocessing device of the present invention presents a new concept of biocomputing system enabling various functions.

Abstract: To provide a process for producing an acrylic rubber/fluorinated rubber composition, capable of forming a layer excellent in the interlayer-adhesion with a layer formed by crosslinking a fluorinated rubber. A process for producing an acrylic rubber/fluorinated rubber composition having particles of a crosslinked acrylic rubber (B) dispersed in a continuous phase of a fluorinated rubber (A), which comprises kneading a fluorinated rubber (A), a crosslinking agent for an acrylic rubber and a crosslinking coagent for an acrylic rubber to obtain a fluorinated rubber composition containing the crosslinking agent for an acrylic rubber and the crosslinking coagent for an acrylic rubber, and kneading under heating the obtained fluorinated rubber composition and an acrylic rubber (B) in a mass ratio of fluorinated rubber (A)/acrylic rubber (B)=5/95 to 50/50 to crosslink the acrylic rubber (B), and dispersing particles of the crosslinked acrylic rubber (B) in a continuous phase of the fluorinated rubber (A).

Abstract: Methods and systems for controlling a polymerization reaction in a non-sticking regime are disclosed. An exemplary method includes measuring parameters for the polymerization reaction including a reactor temperature and a concentration of an induced condensing agent (ICA) in a polymerization reactor. An equivalent partial pressure ((PICA)equiv) of the ICA is calculated. The polymerization reaction is located in a two dimension space defined by a reactor temperature dimension and a ((PICA)equiv) dimension. The location in the two dimensional space is compared to an non-sticking regime, defined as the space between an upper temperature limit (UTL) curve and a lower temperature limit (LTL) curve. The parameters of the polymerization reaction are adjusted to keep the polymerization reaction within the non-sticking regime.

Abstract: A solution process for the polymerization or copolymerization of at least one alpha olefin can include adding a Lewis acid to an alkyl aluminum in a hexane or heptane to form a coordination complex, stirring the coordination complex continuously forming a near homogeneous solution in an inert anhydrous environment, adding at least one dry metallocene to the near homogenous solution forming a soluble polymerization initiator, then stirring to form a near homogenous metallocene enriched polymerization initiator, and polymerizing an alpha olefin with the metallocene enriched polymerization initiator and optionally adding additional alkyl aluminum as a moisture scavenger or an impurities scavenger to yield a poly alpha olefin. The at least one dry metallocene can have a transition metal compound. The Lewis acid is capable of forming an ion pair with the at least one dry metallocene.

Abstract: A homogeneous polymerization catalyst system for polymerization or copolymerization of at least one alpha olefin has a Lewis acid, an alkyl aluminum in a hexane or a heptane, and at least one dry metallocene. The at least one dry metallocene has a transition metal compound. The Lewis acid is capable of forming an ion pair with the at least one dry metallocene. The homogeneous polymerization catalyst system produces a poly alpha olefin from alpha olefin monomers or mixed alpha olefins. A produced poly alpha olefin has a kinematic viscosity at 100 degrees Celsius ranging from 1 cSt to 1000 cSt.

Abstract: Disclosed are an anionic polymerization initiator, which is an organo-alkali metal compound having an anionic end including an amine group, a method of preparing a modified conjugated diene-based polymer using the same, and a rubber composition including the modified conjugated diene-based polymer prepared thereby. Specifically the polydiene and the anionic initiator contain a group of Chemical Formula 8, below, in Chemical Formula 8, R1 and R2 are each independently a C1-C20 alkyl group, R3 is a C1-C10 alkylene group, R4 and R5 each independently a C1-C10 alkyl group, R1 and R2 are linked with each other to form a ring structure, and * represents a bonding position.

Abstract: Catalyst systems and methods for making and using the same. A catalyst system can include a non-metallocene catalyst having the structure: wherein M is a group 4 element, each of R13-R20 are independently a hydrogen or a methyl group, wherein at least one of R13-R20 is a methyl group, Ar is an aryl group or a substituted aryl group, Ar? is an aryl group or a substituted aryl group, and each X is, independently, a hydride group, an amide, a benzyl group, a methyl group, a chloro group, a fluoro group, or a hydrocarbyl group.

Abstract: A resin composition of the present invention includes a polymer compound (A) containing a repeating unit (Q) represented by the following general formula (1): wherein R1 represents a hydrogen atom, a methyl group, or a halogen atom; R2 and R3 represent a hydrogen atom, an alkyl group, or a cycloalkyl group; L represents a divalent linking group or a single bond; Y represents a substituent excluding a methylol group; Z represents a hydrogen atom or a substituent; m represents an integer of 0 to 4; n represents an integer of 1 to 5; and m+n is 5 or less.

Abstract: The invention relates to a process for the preparation of polypropylene having: a molecular weight of 450,000-950,000, a molecular weight distribution of 3-6, and xylene soluble content of 2-6 wt %, by converting propylene into the polypropylene without pre-polymerization in the presence of a polymerization catalyst under a condition where the volume ratio of H2 to propylene is at most 0.0020, wherein the catalyst comprises a catalyst component and a co-catalyst, wherein the catalyst component is obtained by a process wherein a compound with formula Mg(OAlk)xCly wherein x is larger than 0 and smaller than 2, y equals 2?x and each Alk, independently, represents an alkyl group, is contacted with a titanium tetraalkoxide and/or an alcohol in the presence of an inert dispersant to give an intermediate reaction product and wherein the intermediate reaction product is contacted with titanium tetrachloride in the presence of an internal donor.

Abstract: Polymer articles and processes of forming polymer articles are described herein. The processes generally include providing a propylene based polymer formed from a metallocene catalyst and melt processing the propylene based polymer to form a polymer article.

Abstract: A microdroplet or microparticle with Janus or core-shell internal morphology, which is obtained under the control of phase separation of high-concentration NIPAAm formed at 25° C. or more in a microfluidic device, is provided. The microdroplet or microparticle shows an anisotropic volume change according to a change in temperature, and can also serve as a fat-soluble/water-soluble carrier, and thus can be used as a new material for medical supplies in the field of various applications in the future.

Abstract: To provide a water-soluble polythiophene used as an electrically conductive material, and its production method. A polythiophene comprising at least one type of structural units selected from the group consisting of structural units represented by the formula (1), structural units represented by the formula (2), structural units represented by the formula (3), structural units represented by the formula (4), structural units represented by the formula (5) and structural units represented by the formula (6). The polythiophene is obtained by polymerizing at least one thiophene compound selected from the group consisting of a thiophene compound represented by the formula (15), a thiophene compound represented by the formula (16) and a thiophene compound represented by the formula (17) in water or an alcohol solvent in the presence of an oxidizing agent.

Abstract: A process to form an ethylene-based polymer including polymerizing ethylene and at least one asymmetrical polyene comprising an “alpha, beta unsaturated-carbonyl end” (“?,?-unsaturated-carbonyl end”) and a “C—C double bond end,” wherein the polymerization takes place in the presence of at least one free-radical initiator; and wherein the polymerization takes place in a reactor configuration comprising at least two reaction zones, reaction zone 1 and reaction zone i (i>2), wherein reaction zone i is downstream from reaction zone 1.

Abstract: Catalyst systems having both a metallocene catalyst component and a Ziegler-Natta component are disclosed. Such catalyst systems can contain a metallocene compound, an activator-support, an organoaluminum compound, and a Ziegler-Natta component comprising titanium supported on magnesium chloride.

Abstract: Multi-stage polymerization processes that produce polymers having controlled compositions and molecular weight with improved catalyst productivity are disclosed. An example method for producing a multi-modal polyolefin comprises polymerizing the multi-modal polyolefin in the presence of a metallocene catalyst system in at least a slurry-phase polymerization stage and a gas-phase polymerization stage arranged in series in any order, wherein the multi-modal olefin comprises: (i) a first polyolefin fraction having a density of less than about 940 kg/m3, and (ii) a second polyolefin fraction having a density of less than about 930 kg/m3.

Abstract: A polymer compound has a repeating unit represented by Formula 1 and an organic light-emitting display device including the polymer compound. wherein R1, R2, R3, R4, R5, R6, R7, R8, p, a, b, and c are the same as described in the detailed description section of the present specification.

Abstract: Provided is an article having high scratch resistance and satisfactory fingerprint wipeability. Disclosed is an article having a microrelief structure containing a cured product of a resin composition on the surface, in which the indentation elastic modulus (X) [MPa] and the creep deformation ratio (Y) [%] of the cured product satisfy the following formulas (1) and (2): 80?X?560??(1) Y?(0.00022X?0.01)×100??(2).

Abstract: One aspect of the present invention provides an end-modified conjugated diene polymer represented by Formula 1 below: wherein p is a conjugated diene polymer chain; R1 to R7 are each independently C1-C20 saturated or unsaturated hydrocarbon chains; X is carbon (C), silicon (Si), or nitrogen (N); a is 1 or 2; and n is an integer of 1 to 200, and a method for preparing the same.

Abstract: The present invention relates to diene polymers or diene copolymers, wherein the diene polymers or diene copolymers have, at the start of the polymer chains, tertiary amino groups of the formula (Ia), (Ib), (IIa) or (IIb) where R1, R2 are the same or different and are each alkyl, cycloalkyl, aryl, alkaryl and aralkyl radicals which may contain heteroatoms such as O, N, S and/or Si, Z is a divalent organic radical which, as well as C and H, may contain heteroatoms such as O, N, S and/or Si, and, at the end of the polymer chains, silane-containing carbinol groups of the formula (III) or metal salts thereof or semimetal salts thereof, where R3, R4, R5, R6 are the same or different and are each an H or alkyl, cycloalkyl, aryl, alkaryl and aralkyl radicals which may contain heteroatoms such as O, N, S and/or Si, A is a divalent organic radical which, as well as C and H, may contain heteroatoms such as O, N, S and/or Si.

Abstract: The present invention relates to diene polymers, wherein the diene polymers have, at the start of the polymer chains, tertiary amino groups of the formula (I) or (II) where R1, R2 are the same or different and are each alkyl, cycloalkyl, aryl, alkaryl and aralkyl radicals which may contain heteroatoms such as O, N, S and/or Si, Z is a divalent organic radical which, as well as C and H, may contain heteroatoms such as O, N, S and/or Si, and, at the end of the polymer chains, silane-containing carbinol groups of the formula (III) or metal salts thereof or semimetal salts thereof, where R3, R4, R5, R6 are the same or different and are each an H or alkyl, cycloalkyl, aryl, alkaryl and aralkyl radicals which may contain heteroatoms such as O, N, S and/or Si, A is a divalent organic radical which, as well as C and H, may contain heteroatoms such as O, N, S and/or Si.

Abstract: A method of forming lightweight structures from particle networks includes functionalizing edges of particles of an anisotropic material, exfoliating of the particles to form sheets of the material, aligning the sheets of material to form a network of multi-layered and aligned particles, and forming a structure out of the network of particles. One example uses graphite powder mixed into 4-aminobenzoic acid for edge functionalization, and exfoliation occurs with sonication in a solvent. The resulting particles undergo alignment with an aligning nozzle that also dispenses the aligned particles to form a structure.

Abstract: Polyisocyanate-based polymers are formed by curing a reaction mixture containing at least one polyisocyanate and at least one isocyanate-reactive compound having at least two isocyanate-reactive groups in the presence of a copper catalyst that contains at least one copper atom associated with a polydentate ligand that contains at least one nitrogen-containing complexing site.

Abstract: The present invention relates to a composition comprising 10 to 50 wt.-% of at least one polyisocyanate a-1) based on hexamethylene diisocyanate, comprising at least one oligomeric polyisocyanate based on hexamethylene diisocyanate and optionally monomeric hexamethylene diisocyanate and 50 to 90 wt.-% of at least one polyisocyanate a-2) based on isophorone diisocyanate, comprising at least one oligomeric polyisocyanate based on isophorone diisocyanate and optionally monomeric isophorone diisocyanate, with the proviso that at least one of the components a-1) and a-2) additionally comprises monomeric isocyanate of the named kind, as well as at least one sulfur-containing component. It has been shown that the above mentioned mixture of the specific isocyanate group containing components improves the thermal and mechanical properties of a cured composition. Thus prepared molded articles are particularly suitable for the preparation of spectacle lenses, inter alia due to these properties.

Abstract: The invention relates to a method for producing a thermoplastic polyurethane elastomer based on polyether carbonate polyols. The method comprises a first step, in which at least A) an organic diisocyanate and B) a polyol having a number-average molecular weight Mn>=500 and <=5000 g/mol are reacted to form an isocyanate-terminated prepolymer. In a second step, the prepolymer is reacted with C) one or more chain extenders having a molecular weight>=60 and <=490 g/mol and optionally D) a monofunctional chain stopper or E) an organic diisocyanate, wherein optionally at least F) one catalyst is used in the first and/or second step.; The molar ratio of the sum of the isocyanate groups from A) and, if applicable, E) to the sum of the groups reactive to isocyanate in B), C), and, if applicable, D) is >=0.9:1 and <=12:1, and component B) contains at least one polyether carbonate polyol, which can be obtained by adding carbon dioxide and alkylene oxides to H-functional starter substances.

Abstract: A catalyzed interfacial phosgenation process with controlled feed ratios and controlled reaction pH levels allows for the formation of high heat polycarbonate random copolymers having high loadings of bis (4-hydroxyphenyl)-2-phenylisoindolin-1-one (“PPPBP”) or a structurally related comonomer. The process produces a polycarbonate copolymer having improved hydrolytic stability.

Abstract: Provided is (1) a radically polymerizable polyether which imparts excellent mechanical properties including excellent transparency, a high degree of elongation at break and high bending strength to a copolymer produced by the radical polymerization of a radically polymerizable monomer, and a method for producing the radically polymerizable polyether; (2) a polymerizable composition comprising the radically polymerizable polyether and a radically polymerizable vinyl monomer, which enables the formation of a copolymer having excellent mechanical properties; and (3) a copolymer, a molded article and a film, each of which comprises the copolymer.

Abstract: A compound of the formula: (I) wherein: R1 is selected from H, an alkyl group, an aryl group, and combinations thereof; R2 is Rf—Y—(CH2)X—; R3 is a reactive group; Rf is a perfluorinated alkyl group; Y is selected from a bond, S(O)2—N(CH3)—, —S(O)2—N(CH2CH3)—, —S(O)2—O— —S(O)2— —C(O)—, —C(O)—S— —C(O)—O— —C(O)—NH—, —C(O)—N(CH3)—, —C(O)—N(CH2CH3)—, —(CH2CH2O)y-, —O—, and —O—C(O)—CH?CH—C(O)—O—; n is greater than 10; x is 2 to 20; and y is at least 1.

Abstract: Methods for preparation of novel amphiphilic derivatives of thioether containing block copolypeptides with narrow chain length distributions are described. These block copolymers can be chemically modified by oxidation and alkylation of the thioether containing residues. These materials generate self-assembled micelles, vesicles and hydrogels, or emulsions with oil phases. These assemblies can be used to encapsulate and delivery therapeutic molecules. The assemblies can be taken up by cells to release molecules from the assemblies.

Abstract: The methods disclosed herein are directed to methods of enhancing formation of a polymer from a monomer on a metal-based nanoparticle under X-ray irradiation and compositions produced by such methods. The method comprises irradiating a monomer solution with X-rays to form the polymer; wherein the monomer solution comprises the monomer, the metal-based nanoparticle, and a solvent capable of generating a hydroxyl radical; and wherein the metal-based nanoparticle is a particle having a greatest dimension between 5 and 100 nanometers. The methods also include the dissolution metal ions from these same metal-based nanoparticles wherein the solution comprises the metal-based nanoparticle and a solvent capable of generating a hydroxyl radical; and wherein the metal-based nanoparticle is a particle having a greatest dimension between 5 and 100 nanometers.

Abstract: One method as described herein relates to making a high molecular weight, monoesterified polyimide polymer using a small amount of bulky diamine. These high molecular weight, monoesterified polyimide polymers are useful in forming crosslinked polymer membranes with high permeance that are useful for the separation of fluid mixtures. Another method as described herein relates to making the crosslinked membranes from the high molecular weight, monoesterified polyimide polymer containing a small amount of bulky diamine. The small amount of bulky diamine allows for formation of both the high molecular weight polyimide polymer and for covalent ester crosslinks via reaction of the carboxylic acid groups with a diol crosslinking agent. This small amount of bulky diamines reduces chain mobility or segmental motion during crosslinking and reduces large loss of permeance. As such, this method provides a crosslinked membrane with good permeance and selectivity.

Abstract: Disclosed is a block copolymer of the formula: A-B-A (I) or A-B (II), wherein block A is: (i) a polymer of allyl glycidyl ether or (ii) a polymer of allyl glycidyl ether wherein one more of the allyl groups have been replaced with 1,2-dihydroxypropyl group or a group of the formula: —(CH2)a—S—(CH2)b—X, wherein a, b, and X are defined herein. The block copolymers find use as wetting agents in the preparation of porous membranes from aromatic hydrophobic polymers such as polyethersulfone. Also disclosed are methods of preparing such block copolymers and porous membranes therefrom.

Abstract: A curable silicone composition is provided that comprises a reaction product of a reaction of (I) a clustered functional polyorganopolysiloxane having at least one radical curable group selected from an acrylate group and a methacrylate group; (II) a silicone reactive diluent, and a (III) a radical initiator.

Abstract: A room-temperature-curable organopolysiloxane composition contains as essential components (A) an organopolysiloxane shown by the following general formula (1), (B) an alkoxysilane shown by the following general formula (2) or a partial hydrolysate thereof, (C) a silazane compound shown by the following general formula (3), (D) a bismuth compound shown by the following general formula (4) which is in a liquid state at 20° C., a partial hydrolysate thereof, or both of them, (E) one or more fillers, and (F) a silane coupling agent having amine structure or imine structure, in which the composition satisfies [component (C)/component (B)?1.0]. As a result, a room-temperature-curable organopolysiloxane composition has good curability and storage stability even without containing an organotin compound or an organotitanium compound, has safety in view of toxicity to the human body and environment, and exhibits good rubber physical properties and adhesion after curing.